Viewpoint
  • About
    • Overview
    • Awards
    • Partners
    • Pb-203 User Group
  • Technology
    • Theranostics
    • 𝛼-Particle Radiotherapy
    • VMT-𝛼-GEN
    • Publications
  • Pipeline
    • Overview
    • VMT01
    • VMT-𝛼-NET
    • Expanded Access Policy
  • News
    • Press Releases
    • Events
    • Email Alerts
  • Contact
Select Page

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

by Barry | May 24, 2023 | Press Releases

Three poster presentations from Perspective Therapeutics’ scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 203Pb manufacturing, and In Vivo Distribution of Recoiled 213Bi from...

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

by Barry | May 15, 2023 | Press Releases

Additional CDMO capabilities added to increase availability of clinical trial product in the USPhase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and VMT-01 for melanoma RICHLAND, WASHINGTON & CORALVILLE,...

Perspective Therapeutics Announces Changes to the Board of Directors

by Barry | May 15, 2023 | Press Releases

Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the CommitteeMichael McCormick announced his resignation and amicable departure from the Board of...

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

by Barry | Feb 7, 2023 | Press Releases

Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07,...

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

by Barry | Feb 7, 2023 | Press Releases

Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07,...
« Older Entries

Recent Posts

  • Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
  • Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
  • Perspective Therapeutics Announces Changes to the Board of Directors
  • Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
  • Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

Recent Comments

    © 2023 Viewpoint Molecular Targeting®
    • Privacy Policy
    • Terms and Conditions
    • News
    • Contact
    • Follow
    • Follow
    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    SAVE & ACCEPT